68/Strip INR

Product Details:

  • Drug Type General Medicines
  • Product Type Generic Drugs
  • Physical Form Tablets
  • Dosage 50 Mg
  • Supply Ability : 10000 , Per Week
  • Click to view more

Price And Quantity

  • 10000000 ,
  • 68/Strip INR

Product Specifications

  • Generic Drugs
  • 50 Mg
  • General Medicines
  • Tablets

Trade Information

  • Cash in Advance (CID), Cash Advance (CA)
  • 10000 , Per Week
  • 1 Week
  • Free samples are available
  • 100 TABLET
  • Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia

Product Description

Mercaptopurine - Mercaptopurine Was Synthesized And Developed By Hitchings, Elion, And Associates At The Wellcome Research Laboratories. It Is One Of A Large Series Of Purine Analogues Which Interfere With Nucleic Acid Biosynthesis And Has Been Found Active Against Human Leukemias. Mercaptopurine Tablets Are Indicated For Remission Induction And Maintenance Therapy Of Acute Lymphatic Leukemia. The Response To This Agent Depends Upon The Particular Subclassification Of Acute Lymphatic Leukemia And The Age Of The Patient (pediatric Patient Or Adult). Given As A Single Agent For Remission Induction, Mercaptopurine Induces Complete Remission In Approximately 25% Of Pediatric Patients And 10% Of Adults. However, Reliance Upon Mercaptopurine Alone Is Not Justified For Initial Remission Induction Of Acute Lymphatic Leukemia Since Combination Chemotherapy With Vincristine, Prednisone, And L-asparaginase Results In More Frequent Complete Remission Induction Than With Mercaptopurine Alone Or In Combination. The Duration Of Complete Remission Induced In Acute Lymphatic Leukemia Is So Brief Without The Use Of Maintenance Therapy That Some Form Of Drug Therapy Is Considered Essential. Mercaptopurine, As A Single Agent, Is Capable Of Significantly Prolonging Complete Remission Duration; However, Combination Therapy Has Produced Remission Duration Longer Than That Achieved With Mercaptopurine Alone. As A Single Agent, Mercaptopurine Will Induce Complete Remission In Approximately 10% Of Pediatric Patients And Adults With Acute Myelogenous Leukemia Or Its Subclassifications. These Results Are Inferior To Those Achieved With Combination Chemotherapy Employing Optimum Treatment Schedules. Mercaptopurine Is Not Effective For Prophylaxis Or Treatment Of Central Nervous System Leukemia. Mercaptopurine Is Not Effective In Chronic Lymphatic Leukemia, The Lymphomas (including Hodgkin’s Disease), Or Solid Tumors. Active Ingredients: Mercaptopurine


* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.

Developed and Managed by Infocom Network Ltd.